| Dr Harsh Babbar, MD | |
|
1464 E Whitestone Blvd, Suite 601, Cedar Park, TX 78613-9058 | |
| (512) 986-7765 | |
| (512) 986-7608 |
| Full Name | Dr Harsh Babbar |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 26 Years |
| Location | 1464 E Whitestone Blvd, Cedar Park, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114105418 | NPI | - | NPPES |
| 194026401 | Medicaid | TX | |
| 194026402 | Medicaid | TX |
| Facility Name | Location | Facility Type |
|---|---|---|
| Seton Medical Center Williamson | Round rock, TX | Hospital |
| Cedar Park Regional Medical Center | Cedar park, TX | Hospital |
| Seton Northwest Hospital | Austin, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Usacs Critical Care Medicine Services Of Texas Pllc | 1153681796 | 38 |
| Timberland Medical Group | 7719875491 | 39 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.
The sight of a dog in a therapy vest trotting down a hospital hallway or being petted by a child lying in a hospital bed is familiar to many, yet the scientific research showing the impact of therapy animals is largely anecdotal, says Vanderbilt University School of Nursing Professor Mary Jo Gilmer, PhD, FAAN. Her work is changing that.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the second quarter ended June 30, 2010.
The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.
Novartis announced today that the US Food and Drug Administration has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
› Verified 8 days ago
| Entity Name | Travis County Emergency Physicians Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962440933 PECOS PAC ID: 0840289468 Enrollment ID: O20040510000492 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.
The sight of a dog in a therapy vest trotting down a hospital hallway or being petted by a child lying in a hospital bed is familiar to many, yet the scientific research showing the impact of therapy animals is largely anecdotal, says Vanderbilt University School of Nursing Professor Mary Jo Gilmer, PhD, FAAN. Her work is changing that.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the second quarter ended June 30, 2010.
The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.
Novartis announced today that the US Food and Drug Administration has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
› Verified 8 days ago
| Entity Name | Timberland Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528061157 PECOS PAC ID: 7719875491 Enrollment ID: O20040514000302 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.
The sight of a dog in a therapy vest trotting down a hospital hallway or being petted by a child lying in a hospital bed is familiar to many, yet the scientific research showing the impact of therapy animals is largely anecdotal, says Vanderbilt University School of Nursing Professor Mary Jo Gilmer, PhD, FAAN. Her work is changing that.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the second quarter ended June 30, 2010.
The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.
Novartis announced today that the US Food and Drug Administration has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
› Verified 8 days ago
| Entity Name | Austin Critical Care Specialists Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447435805 PECOS PAC ID: 1052497187 Enrollment ID: O20080328000560 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.
The sight of a dog in a therapy vest trotting down a hospital hallway or being petted by a child lying in a hospital bed is familiar to many, yet the scientific research showing the impact of therapy animals is largely anecdotal, says Vanderbilt University School of Nursing Professor Mary Jo Gilmer, PhD, FAAN. Her work is changing that.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the second quarter ended June 30, 2010.
The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.
Novartis announced today that the US Food and Drug Administration has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
› Verified 8 days ago
| Entity Name | Seton Family Of Doctors |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588997233 PECOS PAC ID: 0941333280 Enrollment ID: O20100806000260 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.
The sight of a dog in a therapy vest trotting down a hospital hallway or being petted by a child lying in a hospital bed is familiar to many, yet the scientific research showing the impact of therapy animals is largely anecdotal, says Vanderbilt University School of Nursing Professor Mary Jo Gilmer, PhD, FAAN. Her work is changing that.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the second quarter ended June 30, 2010.
The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.
Novartis announced today that the US Food and Drug Administration has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
› Verified 8 days ago
| Entity Name | Usacs Critical Care Medicine Services Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023522554 PECOS PAC ID: 1153681796 Enrollment ID: O20180131000123 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.
The sight of a dog in a therapy vest trotting down a hospital hallway or being petted by a child lying in a hospital bed is familiar to many, yet the scientific research showing the impact of therapy animals is largely anecdotal, says Vanderbilt University School of Nursing Professor Mary Jo Gilmer, PhD, FAAN. Her work is changing that.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the second quarter ended June 30, 2010.
The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.
Novartis announced today that the US Food and Drug Administration has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Harsh Babbar, MD 6300 La Calma Dr, Suite 200, Austin, TX 78752-3843 Ph: () - | Dr Harsh Babbar, MD 1464 E Whitestone Blvd, Suite 601, Cedar Park, TX 78613-9058 Ph: (512) 986-7765 |
News Archive
Nuvo Research Inc., a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced it will be meeting with several U.S. investment bankers, analysts and fund managers during J.P. Morgan's 29th annual Healthcare Conference held from January 10th to January 13th, 2011, in San Francisco, California.
The sight of a dog in a therapy vest trotting down a hospital hallway or being petted by a child lying in a hospital bed is familiar to many, yet the scientific research showing the impact of therapy animals is largely anecdotal, says Vanderbilt University School of Nursing Professor Mary Jo Gilmer, PhD, FAAN. Her work is changing that.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the second quarter ended June 30, 2010.
The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.
Novartis announced today that the US Food and Drug Administration has approved Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
› Verified 8 days ago
Dr. Seyed Mohammad Abedi, M.D.,PH.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1401 Medical Pkwy Ste 200, Cedar Park, TX 78613 Phone: 512-260-6050 Fax: 512-260-6080 | |
Dr. Geoffrey Michael Crimmins, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1401 Medical Pkwy # B, Ste. 407, Cedar Park, TX 78613 Phone: 512-249-7190 Fax: 512-249-0438 | |
Dr. Lakshmi Balasubramanian, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1401 Medical Parkway Building C, Ste 200, Cedar Park, TX 78613 Phone: 512-260-6050 Fax: 512-260-6080 | |
Dr. Venkatesh Babu G. Segu, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1515 Medical Pkwy Ste 200, Cedar Park, TX 78613 Phone: 512-765-7806 Fax: 512-456-7039 | |
Dr. Richard A Stoebner, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 801 E Whitestone Blvd Ste B, Cedar Park, TX 78613 Phone: 512-259-3467 Fax: 512-496-7303 | |
Dr. Aaron R Kirkpatrick, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1401 Medical Pkwy Ste 419, Cedar Park, TX 78613 Phone: 512-379-3636 Fax: 512-379-3641 | |
Dr. Sarika S Deshmukh, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1460 E Whitestone Blvd Ste 140, Cedar Park, TX 78613 Phone: 512-660-3944 Fax: 512-357-7764 |